Acute Myeloid Leukemia (non-APL) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-OCC-BENZENE-PREVENTION-INTENSIFIED-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-ESMO-MDS-2021` `SRC-NCCN-AML-2025`

Notes

STUB — v0.3 occupational pilot (benzene). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption. No drug regimen — intervention is counseling + CBC surveillance + low-threshold marrow workup. IARC Monograph 100F (2012) is the canonical evidence anchor; v0.3 source-authoring backlog.

Used By

Red flag

RF-OCC-BENZENE-MALIGNANCY-PREVENTION - Documented historical occupational exposure to benzene in an individual without a current...